Capital One analyst Zegbeh Jallah says Kodiak Sciences’ (KOD) Q4 earnings and update was "generally in line with expectations, with a few nice surprises." Kodiak affirmed the Q3 readout of four Phase 3 studies evaluating its lead drug Tarcocimab versus Regeneron’s (REGN) Eylea, while also affirming that patient screening is ongoing for a Phase 1 study of its second drug KSI-501, according to Capital One, which contends that "now is a good time to start accumulating shares" with these upcoming milestones and the company having the cash to execute.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on KOD: